Does Bimzelx Target IL-17?
Yes, Bimzelx (bimekizumab) is an IL-17 inhibitor. It selectively blocks both IL-17A and IL-17F cytokines, which drive inflammation in conditions like plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis.[1][2]
How Does Bimzelx Work Exactly?
Bimekizumab binds to IL-17A and IL-17F with high affinity, preventing these cytokines from interacting with their receptors on immune cells. This dual inhibition sets it apart from drugs like secukinumab or ixekizumab, which target only IL-17A.[1][3]
What Conditions Is Bimzelx Approved For?
Approved in the US and EU for moderate-to-severe plaque psoriasis in adults, and also for psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis in some regions. It's administered via subcutaneous injection every 4-8 weeks after initial doses.[1][2]
How Does Bimzelx Compare to Other IL-17 Inhibitors?
| Drug | Targets | Key Approvals | Dosing Frequency |
|------|---------|---------------|------------------|
| Bimzelx (bimekizumab) | IL-17A + IL-17F | Psoriasis, PsA, axSpA | Every 4-8 weeks |
| Cosentyx (secukinumab) | IL-17A only | Psoriasis, PsA, AS, axSpA | Every 4 weeks |
| Taltz (ixekizumab) | IL-17A only | Psoriasis, PsA, AS | Every 4 weeks |
Bimzelx shows higher skin clearance rates in head-to-head trials against secukinumab.[3][4]
What Side Effects Do Patients Report?
Common issues include upper respiratory infections, oral candidiasis (due to IL-17's role in antifungal defense), and injection-site reactions. Serious risks involve hypersensitivity and increased infection susceptibility; fungal infections occur in up to 10% of users.[1][2]
Who Makes Bimzelx and What's the Patent Status?
UCB Pharma developed and markets Bimzelx. Key US patents expire around 2033-2038, with no generics expected soon. Check DrugPatentWatch.com for litigation updates and exact expiry dates.[5]
[1] Bimzelx US Prescribing Information, UCB Pharma (2023).
[2] EMA Product Information, European Medicines Agency (2023).
[3] Gordon KB et al., Lancet (2021). DOI: 10.1016/S0140-6736(20)32466-9.
[4] Reich K et al., NEJM (2021). DOI: 10.1056/NEJMoa2102383.
[5] DrugPatentWatch.com, Bimekizumab patents (accessed 2024).